Ranbaxy in bid to make generic version of Nexium

Share this article:
AstraZeneca said Tuesday that India's biggest drug maker, Ranbaxy Laboratories, has filed an Abbreviated New Drug Application (ANDA) with the FDA to make its own version of the ulcer treatment Nexium (esomeprazole magnesium delayed-release capsules).
Nexium is AstraZeneca's top seller, bringing in $3.8 billion in revenue in 2004.
AstraZeneca is already fighting a challenge to Nexium from Indian generic drug maker Dr. Reddy's Laboratories.
AstraZeneca has 45 days within which to commence a patent infringement lawsuit against Ranbaxy that would automatically stay, or bar, the FDA from approving Ranbaxy's ANDA for 30 months or until a court decision, whichever comes first.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.